RedHill Biopharma (RDHL) Net Income towards Common Stockholders (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Net Income towards Common Stockholders data on file, last reported at $58.9 million in Q2 2023.

• On a quarterly basis, Net Income towards Common Stockholders rose 294604999900.0% year-over-year to $58.9 million in Q2 2023; TTM through Dec 2024 was $58.9 million, a 15.53% increase from a year earlier, with the FY2025 full-year figure at $7.7 million, up 192.54% from the prior year.
• Net Income towards Common Stockholders for Q2 2023 stood at $58.9 million, up from -$7.9 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for RDHL reached as high as $58.9 million in Q2 2023 and fell as low as -$7.9 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged $3.0 million across 5 years, with a median of $0.05 in 2021.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 294604999900.0% in 2023 and fell as far as 26396666766.67% in 2023.
• Year by year, Net Income towards Common Stockholders stood at $0.03 in 2019, then jumped by 133.33% to $0.07 in 2020, then declined by 28.57% to $0.05 in 2021, then grew by 20.0% to $0.06 in 2022, then soared by 98201666566.67% to $58.9 million in 2023.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $58.9 million in Q2 2023, -$7.9 million in Q1 2023, and $0.06 in Q3 2022.